Preemptive treatment with voriconazole in lung transplant recipients.

Neoh, C F; Snell, G I; Levvey, B; Kotsimbos, T; Morrissey, C O; Slavin, M A; Stewart, K; Kong, D C M

Neoh, C F; Snell, G I; Levvey, B; Kotsimbos, T; Morrissey, C O; Slavin, M A; Stewart, K; Kong, D C M.

Affiliation

Neoh CF; Centre for Medicine Use and Safety, Monash University, Melbourne, Australia.

Transpl Infect Dis ; 15(4): 344-53, 2013 Aug.

Article in En | MEDLINE | ID: mdl-23527908

Subject(s)

Antifungal Agents/therapeutic use; Lung Transplantation/adverse effects; Mycoses/epidemiology; Mycoses/mortality; Pyrimidines/therapeutic use; Triazoles/therapeutic use; Adolescent; Adult; Aged; Aspergillus fumigatus/drug effects; Aspergillus fumigatus/isolation & purification; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Mycoses/microbiology; Mycoses/prevention & control; Retrospective Studies; Treatment Outcome; Voriconazole; Young Adult

Key words

antifungal; lung transplant; post-transplant infection; preemptive; voriconazole

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Triazoles / Lung Transplantation / Mycoses / Antifungal Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google